- AstraZeneca’s Q3 2024 results: Revenue up 21%, EPS up 27%, driven by Oncology, BioPharmaceuticals, Rare Disease demand; 2024 guidance upgraded.
Tue Nov 12 08:02:28 -0000 2024 UTC– AstraZeneca’s CEO, Pascal Soriot, discusses the company’s strong growth in the first nine months of 2024, with revenue and EPS increasing by 21% and 27% respectively in the third quarter.
This growth is attributed to demand for medicines in Oncology, BioPharmaceuticals, and Rare Disease, prompting an upgrade to the full-year 2024 guidance.